EA021994B1 - Антагонисты мускариновых рецепторов ацетилхолина - Google Patents

Антагонисты мускариновых рецепторов ацетилхолина Download PDF

Info

Publication number
EA021994B1
EA021994B1 EA201100019A EA201100019A EA021994B1 EA 021994 B1 EA021994 B1 EA 021994B1 EA 201100019 A EA201100019 A EA 201100019A EA 201100019 A EA201100019 A EA 201100019A EA 021994 B1 EA021994 B1 EA 021994B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
hydroxy
oxy
diphenyl
octane bromide
Prior art date
Application number
EA201100019A
Other languages
English (en)
Russian (ru)
Other versions
EA201100019A1 (ru
Inventor
Драман И. Лэн
Майкл Р. Палович
Брент У. Макклеланд
Кристофер Э. Нейпп
Соня М. Томас
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA021994(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201100019A1 publication Critical patent/EA201100019A1/ru
Publication of EA021994B1 publication Critical patent/EA021994B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
EA201100019A 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина EA021994B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27

Publications (2)

Publication Number Publication Date
EA201100019A1 EA201100019A1 (ru) 2011-12-30
EA021994B1 true EA021994B1 (ru) 2015-10-30

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100019A EA021994B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Country Status (38)

Country Link
US (9) US7498440B2 (Direct)
EP (3) EP1740177B1 (Direct)
JP (2) JP5014121B2 (Direct)
KR (2) KR101152032B1 (Direct)
CN (2) CN102040602A (Direct)
AP (1) AP2213A (Direct)
AR (1) AR050902A1 (Direct)
AU (1) AU2005237576B2 (Direct)
BE (1) BE2014C063I2 (Direct)
BR (1) BRPI0510170B8 (Direct)
CA (2) CA2755954C (Direct)
CY (3) CY1113196T1 (Direct)
DK (2) DK2570128T3 (Direct)
EA (2) EA021994B1 (Direct)
EC (1) ECSP066940A (Direct)
ES (2) ES2392848T4 (Direct)
FR (1) FR14C0075I2 (Direct)
HR (2) HRP20120832T1 (Direct)
HU (2) HUE031304T2 (Direct)
IL (1) IL178152A (Direct)
LT (1) LT2570128T (Direct)
LU (1) LU92565I2 (Direct)
MA (1) MA28631B1 (Direct)
MX (1) MXPA06012405A (Direct)
MY (1) MY144753A (Direct)
NL (1) NL300694I1 (Direct)
NO (3) NO338959B1 (Direct)
NZ (1) NZ549997A (Direct)
PE (1) PE20060259A1 (Direct)
PL (2) PL1740177T3 (Direct)
PT (2) PT2570128T (Direct)
SG (1) SG186597A1 (Direct)
SI (2) SI2570128T1 (Direct)
TW (1) TWI363759B (Direct)
UA (1) UA95768C2 (Direct)
UY (1) UY28871A1 (Direct)
WO (1) WO2005104745A2 (Direct)
ZA (1) ZA200608565B (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
PE20050442A1 (es) * 2003-10-17 2005-07-09 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de receptores muscarinicos de la acetilcolina
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725564A4 (en) * 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1732547B1 (en) * 2004-04-05 2008-08-20 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1957075A4 (en) * 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AU2007242851A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
UY31635A1 (es) 2008-02-06 2009-08-31 Farmacóforos duales-antagonistas muscarínicos de pde4
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP4403231A3 (en) 2009-02-26 2024-10-23 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
PT2899191T (pt) 2009-04-30 2017-11-14 Glaxo Group Ltd Indazoles substituídos com oxazole como inibidores de pi3-cinase
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2528921B1 (en) * 2010-01-28 2017-10-18 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
JP2013529606A (ja) * 2010-06-22 2013-07-22 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗ムスカリン薬含有乾燥粉末配合物
SI2614058T1 (sl) 2010-09-08 2015-10-30 Glaxosmithkline Intellectual Property Development Limited Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012168161A1 (en) * 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
EP2717867A1 (en) 2011-06-08 2014-04-16 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
EP2885298B1 (en) * 2012-08-15 2018-06-13 Glaxo Group Limited Chemical process
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
WO2015007073A1 (zh) * 2013-07-13 2015-01-22 北京市丰硕维康技术开发有限责任公司 奎宁类化合物、其光学异构体及其制备方法和医药用途
KR20160034920A (ko) * 2013-07-30 2016-03-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 과도한 발한의 치료를 위한 국소 조성물 및 그의 사용 방법
CN105611929A (zh) 2013-10-17 2016-05-25 葛兰素史克知识产权开发有限公司 用于治疗呼吸系统疾病的pi3k抑制剂
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
AU2015260841A1 (en) 2014-05-12 2016-12-01 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP4252742A3 (en) 2014-05-28 2023-12-27 GlaxoSmithKline Intellectual Property Development Ltd Fluticasone furoate in the treatment of copd
CA2965590A1 (en) 2014-11-03 2016-05-12 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
WO2017120559A1 (en) * 2016-01-08 2017-07-13 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (Direct) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
FR2585563B1 (fr) 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
EP0944626A4 (en) 1996-12-02 2002-09-04 Univ Georgetown TROPANDERIVATIVES AND METHOD FOR YOUR SYNTHESIS
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
BR0116624A (pt) * 2000-12-28 2003-12-23 Almirall Prodesfarma Ag Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
NZ532283A (en) 2001-10-17 2005-06-24 Ucb S Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
CA2466344A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
BR0215348A (pt) * 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
TW200523261A (en) 2003-07-17 2005-07-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR048573A1 (es) 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
SI1677795T1 (sl) 2003-10-14 2011-04-29 Glaxo Group Ltd Antagonisti muskarinskega acetilholinskega receptorja
PE20050442A1 (es) 2003-10-17 2005-07-09 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de receptores muscarinicos de la acetilcolina
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005051946A2 (en) 2003-11-21 2005-06-09 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005086873A2 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1725236A4 (en) 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
JP2007529514A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
US20070185090A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007538005A (ja) 2004-04-07 2007-12-27 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060367A1 (es) 2004-05-28 2006-04-28 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
WO2006017768A2 (en) 2004-08-05 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1781103A4 (en) 2004-08-06 2008-05-14 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2006050239A2 (en) 2004-10-29 2006-05-11 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008520573A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1957075A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937230A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEDA, K et al. M3 receptor angagonism by the novel antimuscarmic agent solifenacin in the urinary bladder and salivary gland, Naimyn-Schmiedeberg's Arch Pharmacol, 2002, vol. 366, pages 97-103, abstract *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
DK1740177T3 (da) 2012-10-29
NO2017018I1 (no) 2017-05-04
CA2755954A1 (en) 2005-11-10
PL2570128T3 (pl) 2017-09-29
KR101037026B1 (ko) 2011-05-25
US20090124653A1 (en) 2009-05-14
US8183257B2 (en) 2012-05-22
KR20110010841A (ko) 2011-02-07
FR14C0075I1 (fr) 2014-11-21
HK1102423A1 (en) 2007-11-23
BE2014C063I2 (Direct) 2024-08-08
NO2017017I1 (no) 2017-05-04
AP2006003746A0 (en) 2006-10-31
HRP20161385T1 (hr) 2016-12-02
US20140371264A1 (en) 2014-12-18
AR050902A1 (es) 2006-12-06
EP2570128B1 (en) 2016-08-10
US20130030015A1 (en) 2013-01-31
IL178152A0 (en) 2006-12-31
US20120157491A1 (en) 2012-06-21
HUS1400053I1 (hu) 2017-07-28
EP2570128A1 (en) 2013-03-20
AP2213A (en) 2011-03-01
KR101152032B1 (ko) 2012-06-11
BRPI0510170B8 (pt) 2021-05-25
US20150238470A1 (en) 2015-08-27
EP1740177B1 (en) 2012-08-08
PL1740177T3 (pl) 2012-12-31
NO338959B1 (no) 2016-11-07
PT1740177E (pt) 2012-11-02
CY2014043I2 (el) 2015-12-09
SG186597A1 (en) 2013-01-30
ZA200608565B (en) 2019-12-18
TWI363759B (en) 2012-05-11
AU2005237576A1 (en) 2005-11-10
NL300694I2 (Direct) 2015-12-29
CN1976701A (zh) 2007-06-06
MA28631B1 (fr) 2007-06-01
MXPA06012405A (es) 2007-01-17
MY144753A (en) 2011-10-31
EA015033B1 (ru) 2011-04-29
TW200605887A (en) 2006-02-16
BRPI0510170A (pt) 2007-10-02
CA2564742C (en) 2012-01-10
JP5398871B2 (ja) 2014-01-29
EA200601991A1 (ru) 2007-02-27
NO20065417L (no) 2006-12-29
IL178152A (en) 2011-05-31
LU92565I9 (Direct) 2019-01-17
PT2570128T (pt) 2016-10-07
JP2007534769A (ja) 2007-11-29
LU92565I2 (fr) 2014-12-02
US20160002220A1 (en) 2016-01-07
KR20070015412A (ko) 2007-02-02
JP2012162559A (ja) 2012-08-30
US9045469B2 (en) 2015-06-02
ES2392848T3 (es) 2012-12-14
CA2564742A1 (en) 2005-11-10
US7498440B2 (en) 2009-03-03
SI2570128T1 (sl) 2016-11-30
CY2014043I1 (el) 2015-12-09
US8853404B2 (en) 2014-10-07
US8309572B2 (en) 2012-11-13
UY28871A1 (es) 2005-11-30
EA201100019A1 (ru) 2011-12-30
CY1113196T1 (el) 2015-12-09
AU2005237576B2 (en) 2012-01-12
US9144571B2 (en) 2015-09-29
NO2017018I2 (no) 2018-05-14
HUE031304T2 (hu) 2017-07-28
ES2392848T4 (es) 2014-10-01
FR14C0075I2 (fr) 2015-05-22
EP1740177A4 (en) 2010-05-05
DK2570128T3 (en) 2016-11-07
CN102040602A (zh) 2011-05-04
BRPI0510170B1 (pt) 2018-12-18
EP1740177A2 (en) 2007-01-10
HRP20120832T1 (hr) 2012-11-30
EP3111936A1 (en) 2017-01-04
NL300694I1 (Direct) 2015-12-29
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
CY1118082T1 (el) 2017-06-28
CA2755954C (en) 2014-02-18
ECSP066940A (es) 2006-12-20
NZ549997A (en) 2010-10-29
US20070185155A1 (en) 2007-08-09
UA95768C2 (ru) 2011-09-12
SI1740177T1 (sl) 2012-12-31
WO2005104745A3 (en) 2006-08-03
ES2600405T3 (es) 2017-02-08
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
JP5014121B2 (ja) 2012-08-29
LT2570128T (lt) 2016-10-10
WO2005104745A2 (en) 2005-11-10
US7488827B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
EA021994B1 (ru) Антагонисты мускариновых рецепторов ацетилхолина
CN1906183B (zh) N-酰基磺酰胺细胞程序死亡促进剂
KR100362620B1 (ko) 알레르기성질환치료에유용한치환된피페리딘,이를포함하는약제학적조성물및이의제조방법
RU2365588C2 (ru) Хиназолиновые соединения
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP4505227B2 (ja) １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
DE60107221T2 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
EP0844877A1 (en) Use of oxido-squalene cyclase inhibitors to lower blood cholesterol
JP2009540013A5 (Direct)
RU2006127572A (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2003535887A5 (Direct)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2004110717A (ru) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
EA015714B1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма, и лечение ассоциированных с ним рассройств
WO2001025228A1 (en) Amine derivatives
JP2016536333A5 (Direct)
JPWO2020038415A5 (Direct)
JPWO2005097738A1 (ja) 新規スルホンアミド誘導体
JPWO2019014100A5 (Direct)
BRPI0213393B1 (pt) derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
NL1028193C2 (nl) Farmaceutisch werkzame verbindingen.
JP2002505286A5 (Direct)
EP0775138B1 (en) TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO 2,3-b]PYRIDINE
JP2004507527A5 (Direct)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM